公开(公告)号：US11167034B2

公开(公告)日：2021-11-09

申请号：US16619427

申请日：2018-06-13

申请人： The University of British Columbia

发明人： John K. Jackson ,  Martin E. Gleave ,  Veronika Schmitt ,  Claudia Kesch

IPC分类号： A61K47/34 ,  A61K9/06 ,  A61K47/10

摘要： This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.

公开(公告)号：US11142561B2

公开(公告)日：2021-10-12

申请号：US15737605

申请日：2016-06-29

申请人： THE UNIVERSITY OF BRITISH COLUMBIA

发明人： Christopher J. Ong ,  James William Peacock ,  Martin E. Gleave

IPC分类号： C07K14/705 ,  A61P35/00 ,  A61K45/06

摘要： Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.

公开(公告)号：US20190201528A1

公开(公告)日：2019-07-04

申请号：US16046812

申请日：2018-07-26

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  Centre for Drug Research and Development

发明人： Helen M. Burt ,  Donald E. Brooks ,  Jayachandran N. Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

IPC分类号： A61K47/10 ,  C08G65/333 ,  A61K33/24 ,  A61K31/407 ,  A61K31/337 ,  C08G83/00 ,  A61K47/60 ,  A61K9/51 ,  C08G65/48 ,  C08G65/34 ,  A61K47/34

摘要： Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

公开(公告)号：US09561278B2

公开(公告)日：2017-02-07

申请号：US14868148

申请日：2015-09-28

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  Centre for Drug Research and Development

发明人： Helen M. Burt ,  Donald E. Brooks ,  Jayachandran N. Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

IPC分类号： A61K47/10 ,  A61K31/337 ,  A61K31/407 ,  A61K9/51 ,  A61K47/34 ,  C08G65/34 ,  C08G65/48 ,  C08G83/00 ,  C08G65/333 ,  A61K33/24 ,  A61K9/00

CPC分类号： A61K47/10 ,  A61K9/0034 ,  A61K9/006 ,  A61K9/5146 ,  A61K31/337 ,  A61K31/407 ,  A61K33/24 ,  A61K47/34 ,  A61K47/60 ,  C08G65/33306 ,  C08G65/33337 ,  C08G65/34 ,  C08G65/48 ,  C08G83/005 ,  C08G83/006 ,  C08G2650/54

摘要： Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

摘要翻译： 本文提供衍生的超支化聚甘油（“dHPG”）。 dHPG包含核心，其包含用C1C20烷基链衍生的超支化聚甘油和包含至少一个与核心羟基结合的亲水取代基的壳，其中超支化聚甘油包含约1至约200摩尔的至少一个亲水取代基 。 dHPG用作将药物或其他生物活性部分递送至尿路，消化道，气道，阴道腔和子宫颈以及腹膜腔以治疗诸如癌症的适应症的药剂，其可能是有用的 在制备中用于治疗癌症的药物组合物的治疗或制造中，作为用于改善组织中药物摄取的预处理或共处理。 此外，还提供了制备dHPG的方法。

公开(公告)号：US20160168577A1

公开(公告)日：2016-06-16

申请号：US14932396

申请日：2015-11-04

申请人： The University of British Columbia

发明人： Martin E. Gleave ,  Scott D. Cormack

IPC分类号： C12N15/113 ,  A61K31/711 ,  A61K31/337 ,  A61K31/7068 ,  A61K33/24

CPC分类号： C12N15/1137 ,  A61K31/337 ,  A61K31/7052 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K33/24 ,  A61N5/10 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/31 ,  C12N2310/3525

摘要： A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.

摘要翻译： 提供了减少簇蛋白表达以提供治疗癌症方面的治疗益处的反义治疗方法，包括向需要治疗表达聚集蛋白的癌症的患者给予40至640mg抗聚集蛋白反义寡核苷酸。 该方法可以包括施用化学治疗剂或药剂，放射疗法和/或激素消融治疗。 本发明还包括配制成提供40至640mg的剂量的药物组合物，以及在配制药物中使用反义物。

公开(公告)号：US09200285B2

公开(公告)日：2015-12-01

申请号：US14247799

申请日：2014-04-08

申请人： The University of British Columbia

发明人： Martin E. Gleave ,  Scott D. Cormack

IPC分类号： C12N15/113 ,  A61K31/7088 ,  A61K31/711 ,  C12N15/11 ,  A61K31/7052 ,  A61K31/337 ,  A61K31/7068 ,  A61K31/7105 ,  A61K33/24 ,  A61N5/10

CPC分类号： C12N15/1137 ,  A61K31/337 ,  A61K31/7052 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K33/24 ,  A61N5/10 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/31 ,  C12N2310/3525

摘要： A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.

摘要翻译： 提供了减少簇蛋白表达以提供治疗癌症方面的治疗益处的反义治疗方法，包括向需要治疗表达聚集蛋白的癌症的患者给予40至640mg抗聚集蛋白反义寡核苷酸。 该方法可以包括施用化学治疗剂或药剂，放射疗法和/或激素消融治疗。 本发明还包括配制成提供40至640mg的剂量的药物组合物，以及在配制药物中使用反义物。

公开(公告)号：US09085769B2

公开(公告)日：2015-07-21

申请号：US14288030

申请日：2014-05-27

申请人： The University of British Columbia

发明人： Martin E. Gleave ,  Palma Rocchi ,  Maxim Signaevsky ,  Eliana Beraldi

IPC分类号： C07H21/02 ,  C07H21/04 ,  A61K48/00 ,  C12N15/113 ,  A61K31/7125 ,  A61K31/713

CPC分类号： C12N15/113 ,  A61K31/337 ,  A61K31/7068 ,  A61K31/7088 ,  A61K31/7125 ,  A61K31/713 ,  A61K48/005 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2320/30 ,  C12N2320/31

摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

公开(公告)号：US20150050285A1

公开(公告)日：2015-02-19

申请号：US14372972

申请日：2013-02-01

申请人： The University of British Columbia

发明人： Martin E. Gleave ,  Amina Zoubeidi ,  Masafumi Kumano

IPC分类号： A61K39/395 ,  A61K31/5377 ,  A61K31/7088 ,  A61K31/517

CPC分类号： A61K39/3955 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/7088 ,  A61K31/713 ,  A61K2039/505 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31

摘要： Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or antifolates.

摘要翻译： 癌症的联合治疗使用HSP27抑制剂和EGFR酪氨酸激酶抑制剂或抗叶酸剂。

公开(公告)号：US10071160B2

公开(公告)日：2018-09-11

申请号：US15388676

申请日：2016-12-22

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  Centre for Drug Research and Development

发明人： Helen M. Burt ,  Donald E. Brooks ,  Jayachandran N. Kizhakkedathu ,  Richard Liggins ,  Dechi Guan ,  Lu Ye ,  Clement Mugabe ,  Alan So ,  Martin E. Gleave ,  John K. Jackson ,  Rajesh Kumar Kainthan

IPC分类号： A61K47/10 ,  A61K33/24 ,  A61K31/407 ,  A61K31/337 ,  A61K9/51 ,  A61K47/34 ,  C08G65/34 ,  C08G65/48 ,  C08G83/00 ,  C08G65/333 ,  A61K47/60 ,  A61K9/00

CPC分类号： A61K47/10 ,  A61K9/0034 ,  A61K9/006 ,  A61K9/5146 ,  A61K31/337 ,  A61K31/407 ,  A61K33/24 ,  A61K47/34 ,  A61K47/60 ,  C08G65/33306 ,  C08G65/33337 ,  C08G65/34 ,  C08G65/48 ,  C08G83/005 ,  C08G83/006 ,  C08G2650/54

摘要： Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

公开(公告)号：US20180162923A1

公开(公告)日：2018-06-14

申请号：US15737605

申请日：2016-06-29

申请人： THE UNIVERSITY OF BRITISH COLUMBIA

发明人： Christopher J. Ong ,  James Peacock ,  Martin E. Gleave

IPC分类号： C07K14/705 ,  A61K45/06 ,  A61P35/00

CPC分类号： C07K14/70546 ,  A61K45/06 ,  A61P35/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/31

摘要： Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.